A Look At Fisher & Paykel Healthcare (NZSE:FPH) Valuation After Upgraded Full Year Revenue And Profit Guidance

Simply Wall St.05:37

Fisher & Paykel Healthcare (NZSE:FPH) has raised its full year guidance, now projecting operating revenue of about $2.30b and net profit after tax between $450m and $470m for the year ending 31 March ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2614724933?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/company-cover/875015-main-header/1585186825715","is_english":true,"pubTime":"2026-02-25 05:37","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2614724933","market":"sg","top_or_hot":-1,"title":"A Look At Fisher & Paykel Healthcare (NZSE:FPH) Valuation After Upgraded Full Year Revenue And Profit Guidance","media":"Simply Wall St.","content":"<div>\n<p>Fisher & Paykel Healthcare (NZSE:FPH) has raised its full year guidance, now projecting operating revenue of about $2.30b and net profit after tax between $450m and $470m for the year ending 31 March ...</p>\n\n<a href=\"https://simplywall.st/stocks/nz/healthcare/nzx-fph/fisher-paykel-healthcare-shares/news/a-look-at-fisher-paykel-healthcare-nzsefph-valuation-after-u\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>A Look At Fisher & Paykel Healthcare (NZSE:FPH) Valuation After Upgraded Full Year Revenue And Profit Guidance</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nA Look At Fisher & Paykel Healthcare (NZSE:FPH) Valuation After Upgraded Full Year Revenue And Profit Guidance\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-02-25 05:37 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/nz/healthcare/nzx-fph/fisher-paykel-healthcare-shares/news/a-look-at-fisher-paykel-healthcare-nzsefph-valuation-after-u><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Fisher & Paykel Healthcare (NZSE:FPH) has raised its full year guidance, now projecting operating revenue of about $2.30b and net profit after tax between $450m and $470m for the year ending 31 March ...</p>\n\n<a href=\"https://simplywall.st/stocks/nz/healthcare/nzx-fph/fisher-paykel-healthcare-shares/news/a-look-at-fisher-paykel-healthcare-nzsefph-valuation-after-u\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"XLV","symbol_name":"健康照护类股ETF-SPDR","start_time":0,"source_url":"https://simplywall.st/stocks/nz/healthcare/nzx-fph/fisher-paykel-healthcare-shares/news/a-look-at-fisher-paykel-healthcare-nzsefph-valuation-after-u","article_id":"2614724933","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/company-cover/875015-main-header/1585186825715"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/nz/healthcare/nzx-fph/fisher-paykel-healthcare-shares/news/a-look-at-fisher-paykel-healthcare-nzsefph-valuation-after-u","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2614724933","pubTimestamp":1771969024,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Fisher & Paykel Healthcare (NZSE:FPH) has raised its full year guidance, now projecting operating revenue of about $2.30b and net profit after tax between $450m and $470m for the year ending 31 March 2026.\nSee our latest analysis for Fisher & Paykel Healthcare.\nThe raised guidance comes as the share price has gained 11.24% over the past week and 5.36% year to date. The 1 year total shareholder return of 16.63% and 3 year total shareholder return of 60.45% point to momentum that has built over...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":["rate","earning"],"viewcount":null,"language":"en","relate_stocks":{"XLV":"健康照护类股ETF-SPDR","FPH.NZ":"Fisher & Paykel Healthcare Corporation Limited Ord Shares","FPH":"五点控股"},"translate_title":"上调全年收入和利润指引后斐雪派克医疗保健(NZSE：FPH)估值","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"FPH":1.5,"FPH.NZ":1.5,"XLV":1.5},"content_text":"Fisher & Paykel Healthcare (NZSE:FPH) has raised its full year guidance, now projecting operating revenue of about $2.30b and net profit after tax between $450m and $470m for the year ending 31 March 2026. See our latest analysis for Fisher & Paykel Healthcare. The raised guidance comes as the share price has gained 11.24% over the past week and 5.36% year to date. The 1 year total shareholder return of 16.63% and 3 year total shareholder return of 60.45% point to momentum that has built over time rather than appearing suddenly. If this guidance update has you thinking about what else could be shaping healthcare, it might be worth checking out 111 healthcare AI stocks as a starting list of companies to research next. With guidance now pointing to about NZ$2.30b in revenue and NZ$450m to NZ$470m in net profit, and the share price already up strongly, you have to ask yourself whether there is still a buying opportunity here or if the market is already pricing in future growth. AdvertisementMost Popular Narrative: 2.7% Undervalued Fisher & Paykel Healthcare's most followed valuation narrative pegs fair value at about NZ$40.81 per share, just above the last close of NZ$39.69. This sets up a fairly tight valuation gap for investors to weigh.  The analysts have a consensus price target of NZ$35.683 for Fisher & Paykel Healthcare based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of NZ$40.9, and the most bearish reporting a price target of just NZ$27.0.  Read the complete narrative. Want to see what is sitting behind that tight fair value band and the higher end of analyst targets? Revenue, earnings, and margins are all modeled in detail. The key assumptions pull together growth, profitability, and the cost of capital into one story. If you are curious which forecasts justify that NZ$40.81 figure, the full narrative lays the numbers out clearly. Result: Fair Value of NZ$40.81 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, the story could change quickly if hospital budgets tighten or new product uptake slows, which might challenge current margin assumptions and earnings forecasts. Find out about the key risks to this Fisher & Paykel Healthcare narrative. Another View: Earnings Multiple Sends A Different Signal Those fair value models suggest Fisher & Paykel Healthcare is only about 2.7% undervalued at NZ$39.69 versus a fair value of NZ$40.81. The P/E ratio tells a sharper story. At 53.3x, it is well above the global Medical Equipment average of 27.9x, the peer average of 47.7x and even the fair ratio of 23.8x that our work suggests the market could eventually lean toward. This raises the question of how much valuation risk you are comfortable taking if sentiment cools. See what the numbers say about this price — find out in our valuation breakdown. NZSE:FPH P/E Ratio as at Feb 2026Next Steps With sentiment this mixed, it makes sense to look through the numbers yourself, act while the data is fresh, and weigh up 2 key rewards to round out your view. Looking for more investment ideas? If this update has sharpened your focus, it may be a good time to widen the lens and line up a few more ideas worth serious attention.  Target potential mispricings by scanning companies our tools highlight as 231 high quality undervalued stocks, and see which ones deserve a spot on your watchlist. Build a steadier income stream by checking out 441 dividend fortresses, focused on companies offering higher yields with the potential for more reliable payouts. Sleep a little easier by reviewing 321 resilient stocks with low risk scores, a curated set of businesses that score well on financial resilience and risk factors.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2614724933","isCrawlerRequest":true}